Humacyte (NASDAQ:HUMA – Get Free Report) will be issuing its quarterly earnings data before the market opens on Friday, March 22nd. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Humacyte Trading Down 0.6 %
Shares of HUMA opened at $3.49 on Wednesday. The company has a quick ratio of 6.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.46. Humacyte has a 12-month low of $1.96 and a 12-month high of $5.60. The firm has a market capitalization of $361.48 million, a PE ratio of -4.01 and a beta of 1.53. The stock’s fifty day simple moving average is $3.46 and its 200-day simple moving average is $3.00.
Analysts Set New Price Targets
HUMA has been the topic of several analyst reports. Benchmark cut their target price on Humacyte from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, December 27th. HC Wainwright initiated coverage on Humacyte in a research report on Monday, December 11th. They issued a “buy” rating and a $6.00 price objective for the company.
Hedge Funds Weigh In On Humacyte
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Humacyte by 13.2% during the second quarter. BlackRock Inc. now owns 4,304,505 shares of the company’s stock worth $12,311,000 after purchasing an additional 501,265 shares during the period. Vanguard Group Inc. boosted its position in Humacyte by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,123,266 shares of the company’s stock worth $8,870,000 after purchasing an additional 104,299 shares during the period. Geode Capital Management LLC boosted its position in shares of Humacyte by 4.6% in the second quarter. Geode Capital Management LLC now owns 1,101,967 shares of the company’s stock valued at $3,152,000 after acquiring an additional 48,034 shares during the period. State Street Corp boosted its position in shares of Humacyte by 57.3% in the second quarter. State Street Corp now owns 1,039,280 shares of the company’s stock valued at $2,972,000 after acquiring an additional 378,485 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Humacyte by 9.0% in the fourth quarter. Northern Trust Corp now owns 565,107 shares of the company’s stock valued at $1,605,000 after acquiring an additional 46,521 shares during the period. 27.36% of the stock is owned by institutional investors.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
Further Reading
- Five stocks we like better than Humacyte
- The Role Economic Reports Play in a Successful Investment Strategy
- Growing Twice as Fast as Tesla, XPeng is a Buy
- How to Capture the Benefits of Dividend Increases
- 4 Stocks Building Long-Term Value for ShareholdersÂ
- Low PE Growth Stocks: Unlocking Investment Opportunities
- FedEx Stock Has Analysts Upgrading in Bulk, a Sudden Discount
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.